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Abstract
Background: Post-partum haemorrhage (PPH) is a leading cause of maternal death worldwide. The WOMAN trial
assessed the effects of tranexamic acid (TXA) on death and surgical morbidity in women with PPH. The trial
recorded 483 maternal deaths. We report the circumstances of the women who died.
Methods: The WOMAN trial recruited 20,060 women with a clinical diagnosis of PPH after a vaginal birth or
caesarean section. We randomly allocated women to receive TXA or placebo. When a woman died, we asked
participating clinicians to report the cause of death and to provide a short narrative of the events surrounding the
death. We collated and edited for clarity the narrative data.
Results: Case fatality rates were 3.0% in Africa and 1.7% in Asia. Nearly three quarters of deaths were within 3 h of
delivery and 91% of these deaths were from bleeding. Women who delivered outside a participating hospital (12%)
were three times more likely to die (OR = 3.12, 95%CI 2.55–3.81) than those who delivered in hospital. Blood was
often unavailable due to shortages or because relatives could not afford to buy it. Clinicians highlighted late
presentation, maternal anaemia and poor infrastructure as key contributory factors.
Conclusions: Although TXA use reduces bleeding deaths by almost one third, mortality rates similar to those in
high income countries will not be achieved without tackling late presentation, maternal anaemia, availability of
blood for transfusion and poor infrastructure.
Background
Post-partum haemorrhage (PPH), the leading cause of
maternal death worldwide, accounts for about 19.7% of
maternal deaths [1, 2]. There are considerable variations
across regions with for instance PPH accounting for
about 8.0% of maternal deaths in developed countries
compared to 19.7% in the developing countries [1]. Ma-
ternal outcomes for obstetric haemorrhages, e.g. PPH,
are also more severe in developing countries [3]. This
disparity between developed and developing areas may
be explained by the limited resources in the latter. Some
of the deficiencies in the health systems include insuffi-
cient availability of properly formed birth attendants
both in hospitals and to assist home births, insufficient
emergency transport to a facility with better expertise,
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and limited availability of blood products and blood
banks [4].
The WOMAN Trial was a large, international, rando-
mised trial to assess the effects of tranexamic acid (TXA)
on death and surgical interventions in women with PPH
[5]. In 2017, we reported that early administration of TXA
reduces death due to bleeding after PPH by about one
third with no evidence of adverse effects [5].
Because TXA is a haemostatic drug, we hoped that it
would reduce death from bleeding, but we did not ex-
pect any reduction in deaths unrelated to bleeding (e.g.
from infection or eclampsia) [6]. For this reason, we re-
corded information on the cause of death in the
WOMAN trial. Although assigning cause requires judge-
ment, in a blinded clinical trial any inaccuracy will be
unrelated to treatment allocation and should not cause
bias. Nevertheless, to verify the accuracy of the cause of
death, we asked doctors to provide a short narrative ac-
count of the events surrounding the death. In the
WOMAN trial, 483 of the enrolled women died. The
narratives of their deaths, although sometimes just a few
lines written by the doctor who witnessed it, were help-
ful to shed some light on the circumstances of the
women who died, revealing details otherwise not cap-
tured bythe trial data.
In this paper, we draw on these narratives to illumin-
ate maternal death following a diagnosis of PPH. We
hope that this will facilitate a deeper understanding of
the risk factors for PPH death as well as of the circum-
stances of the women who die and of the doctors who
care for them.
Methods
The WOMAN trial was a randomised, placebo-
controlled trial of the effect of TXA on death and mater-
nal morbidity in women with PPH [5]. It included 20,
060 women aged 16 years and older with a clinical diag-
nosis of PPH recruited from 193 hospitals in 21 coun-
tries between 2010 and 2016. Participating hospitals
were selected on their ability to provide Comprehensive
Emergency Obstetric Care, i.e. hospital care provision
had to include parenteral administration of antibiotics,
uterotonic drugs and parenteral anticonvulsants, manual
removal of placenta, removal of retained products, per-
formance of assisted vaginal delivery and neonatal resus-
citation, blood transfusion and caesarean section services
[7]. The fundamental eligibility criteria for women re-
cruited into the trial were a diagnosis of PPH after a va-
ginal birth or caesarean section and the clinician’s
uncertainty about whether to use TXA in particular a
woman with PPH [5, 8]. The clinical diagnosis of PPH
could be based on the clinical estimation of blood loss.
After confirming eligibility and completing the consent
procedures, we collected baseline data on the trial entry
form completed just before randomisation. We ran-
domly allocated women to receive an intravenous injec-
tion of 1 g of TXA or matching placebo by selection of a
blinded treatment pack. If bleeding continued after 30
min or restarted within 24 h of the first dose, we gave a
second dose of 1 g of TXA or placebo. We have pub-
lished a detailed account of the trial rationale, design,
eligibility criteria, methods, results, and ethics committee
approvals elsewhere [5, 8]. A written informed consent
was obtained for each participant according to the pro-
cedures detailed in Shakur et al. [8]. The study was ap-
proved by the UK National Research Ethics Service
(Berkshire Research Ethics Committee reference number
10/H0505/111) and by the London School of Hygiene
and Tropical Medicine Ethics Committee (reference
number 5536).
We recorded outcome data at death, discharge or 6
weeks (42 days) after randomisation (whichever occurred
first). We obtained follow-up data for 99.8% of women.
Doctors sent the data to the coordinating centre by dir-
ect entry into an electronic database, by fax or via
encrypted data forms (sent by email, or uploaded to a
secure server). We monitored adherence to the protocol
and data quality by central monitoring, statistical data
checking, and site visits, during which we conducted
source data verification.
Whenever a woman died, we asked the obstetrician to
record the immediate cause of the death (the final
pathophysiological process leading to death). If there
was more than one immediate cause, we asked for the
most important. We also asked for a short narrative ac-
count of the events surrounding the death. The chief in-
vestigator and project director reviewed the narratives
and if they appeared inconsistent with the given cause of
death, we asked the obstetrician to review the cause of
death (although in each case the judgement of the ob-
stetrician prevailed). In most cases, a post-mortem
examination was not conducted due to cultural or other
local reasons. Narratives were reviewed to identify if
contributing factors were mentioned in relation to the
deaths. The qualitative narratives were managed in
NVivo 11 (released 2015, QSR International) and cause
of death and contributing factors were identified using a
thematic analysis. We edited the narrative data to cor-
rect spelling and punctuation and we removed any iden-
tifying information related to the participant. Quotes are
identified by numbers referring to their positions in the
supplementary material (Table S1).
We conducted univariable analyses to describe risk
factors for death and the characteristics of the study
population that were collected from the trial entry
forms. We conducted statistical analysis using Stata Stat-
istical Software: Release 15 (College Station, TX: Stata-
Corp LLC).
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Results
Most of the 20,060 trial participants were recruited in
Africa (12,343) and Asia (6030). There were 483 mater-
nal deaths with case fatality rates of 3.0% (375 women)
and 1.7% (105 women) in Africa and Asia, respectively.
In Europe, 1049 women were recruited and none died.
We obtained narratives for 52% of the women who died.
We show the baseline characteristics of the 483
women who died in Table 1. The odds of death in-
creased with increasing age. The odds of death for
mothers with stillbirths was five times higher than for
those with live infants. Over one third of the women
who died (35.1%) gave birth to a stillborn baby, com-
pared to less than one tenth (9.3%) of those who sur-
vived. High estimated blood loss (> 1000mL),
hypotension (systolic blood pressure < 90 mmHg) and
haemodynamic instability (based on clinical signs such
as low blood pressure, tachycardia, falling urine output
that require interventions such as the administration of
intravenous fluids) were strongly associated with the risk
of death. Within 3 h from delivery, 13.3% of the 483
women died, and an additional 59.8% died between 3
and 24 h post-delivery. The maximum survival time was
28.7 days.
Although most of the trial participants (88.0%) gave
birth in a participating hospital, 12.0% gave birth else-
where and were brought to the hospital for emergency
care. These women were over three times more likely to
die (OR = 3.12, 95%CI 2.55–3.81). Of the women who
gave birth elsewhere, 38.8% had a blood pressure below
90mmHg, and 79.8% showed signs of haemodynamic in-
stability, compared to 16.5 and 56.2% of those who deliv-
ered in hospital, respectively. Blood transfusions were
given to 79.0% of women who did not deliver in a hos-
pital compared to 51.4% of those who did. Of the
women who delivered outside a hospital, 5.8% died com-
pared with 1.9% of those who delivered in hospital.
“The mother was referred from another health unit
where she had delivered and bled profusely. She only
stayed with us for about 40 minutes and died during
resuscitation before she was transfused.” (quote 162,
Table S1)
“The patient was an un-booked gravida 3 para 2,
brought by a TBA [traditional birth attendant] from
home with APH [ante-partum haemorrhage] and
prolonged labour. Laparotomy revealed extensive
uterine rupture and large amount of internal
bleeding. She died on the theatre table while
resuscitative efforts were still on-going.” (quote 156,
Table S1)
“Following an unsupervised home delivery of a set of
twins, the placentae of the babies were retained. All
efforts to remove them at the facilities she got to were
unsuccessful until she got to [named hospital], by
which time we estimated she would have lost about
2000 mls of blood. Under halothane, another
attempt at removal was made yielding only a ragged
placenta and a possibly adherent second one. In
view of the bleeding, the doctors proceeded to
hysterectomy. However, she expired after 4 hours
post operatively.” (quote 191, Table S1)
Women sometimes arrived at hospital from other health
facilities where they gave birth and were already in a
critical condition upon arrival at the hospital.
“Delivered vaginally in a private clinic to a stillbirth.
… Referred to our unit with post-partum
haemorrhage. Admitted in our unit at midnight in
shock, no recordable blood pressure, cold extremities,
pre renal failure, gasping breath sounds, atonic
uterus. Evacuated more than one litre of blood clots
from her uterus. The amount of blood loss before
admission not indicated in the referral note. Started
on IV fluids ... Started on blood transfusion, bleeding
stopped one hour later at 2am, uterus well
contracted. Blood pressure improved to 90/50.
Received 2 units of whole blood and 2 units of fresh
frozen plasma. At 5am developed profuse vaginal
bleeding with atonic uterus again, prepared for
theatre, no more blood available in our blood bank,
intubated but arrested before further treatment.”
(quote 160, Table S1)
“The patient had an emergency Caesarean section
performed in another health unit and was referred
to [named hospital] hospital due to continued per
vaginal bleeding- PPH. On arrival, she was in
critical condition, unconscious with cardiovascular
collapse. Her clothing was all soiled with blood and
she had active per vaginal bleeding. There were no
obvious signs of free peritoneal fluid. Uterus was at
about 22 weeks.” (quote 181, Table S1)
“Patient underwent c/section at peripheral hospital
and was referred to our hospital in state of shock.
After resuscitating the patient, a laparotomy was
arranged because patient did not respond to non-
surgical interventions and there was worsening
hemoperitonium. Surgery revealed that there was
uterine atony and massive hemoperitonium, several
uterotonic drugs and tranexamic acid was given. In
the meantime, patient became hemodynamically
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unstable when hysterectomy was performed.” (quote
232, Table S1)
Several of the death narratives highlighted the contribu-
tion of severe anaemia which complicated emergencies
where blood for transfusions was not readily available.
“Had induction of labour on account of
intrauterine foetal death but suffered from PPH
with severe anaemia. … She could only get a
pint of blood and efforts to get more blood for
further transfusion was on-going when she died.”
(quote 126, Table S1)
Table 1 Baseline characteristics and stillbirths of women in the WOMAN trial who survived, and of the women who died. The
second and third columns report the number of women in each category and the corresponding percentage. The fourth and fifth
columns report the odds ratios, and the P values calculated from the likelihood ratio test
n (%) alive n (%) dead OR (95% CI) P-value
Age at randomisation (years)
≤ 25 6738 (34.49) 104 (21.53) 1 < 0.001
26–35 10,703 (54.78) 284 (58.80) 1.72 (1.37–2.16)
≥ 36 2090 (10.70) 95 (19.67) 2.94 (2.22–3.91)
Missing 7 (0.04) 0.0
Baby delivered in hospital
Yes 17,249 (88.28) 341 (70.60) 1 < 0.001
No 2287 (11.71) 141 (29.19) 3.12 (2.55–3.81)
Missing 2 (0.01) 1 (0.21)
Type of delivery
Vaginal 13,871 (70.99) 320 (66.25) 1 0.03
Caesarean section 5663 (28.98) 162 (33.54) 1.24 (1.02–1.50)
Missing 4 (0.02) 1 (0.21)
Systolic BP (mmHg)
< 90 3560 (18.22) 276 (57.14) 6.13 (5.05–7.45) < 0.001
90–120 13,446 (68.82) 170 (35.20) 1
121–140 1775 (9.08) 25 (5.18) 1.11 (0.73–1.70)
> 140 752 (3.85) 12 (2.48) 1.26 (0.70–2.28)
Missing 5 (0.03) 0.0
Estimated volume of blood lost (mL)
≤ 1000 10,327 (52.86) 77 (15.94) 1 < 0.001
1001–2000 8072 (41.31) 213 (44.10) 3.54 (2.72–4.60)
> 2000 1137 (5.82) 193 (39.96) 22.77 (17.36–29.86)
Missing 2 (0.01) 0.0
Haemodynamic instability
No 8168 (41.81) 26 (5.38) 1 < 0.001
Yes 11,369 (58.19) 457 (94.62) 12.63 (8.50–18.77)
Missing 1 (0.01) 0.0
Primary cause of haemorrhage
Uterine atony 12,504 (64.00) 257 (53.21) 1 < 0.001
Placenta praevia/accreta 1835 (9.39) 40 (8.28) 1.06 (0.76–1.49)
Surgical trauma/tears 3582 (18.33) 99 (20.50) 1.34 (1.06–1.70)
Other/Unknown 1617 (8.28) 87 (18.01) 2.62 (2.04–3.36)
Stillbirths
No 17,716 (90.67) 313 (64.80) 1 < 0.001
Yes 1817 (9.30) 169 (34.99) 5.26 (4.34–6.39)
Missing 5 (0.03) 1 (0.21)
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“The main cause of death was the anaemia which
became complicated by heart failure from which she
never recovered. If we had been able to rescue her
from the failure, we would have had enough time to
treat the pneumonia.” (quote 114, Table S1)
“PPH is an emergency and usually many things are
done simultaneously, … she died because of severe
blood loss/preexisting anaemia and lack of more
blood for transfusion.” (quote 168, Table S1)
“Delivered in an outside facility, admitted to our site
post-partum. ... Reported to have sickle cell anaemia,
but this could not be confirmed before she died.
Relatives were unable to pay or donate for further
blood transfusion.” (quote 170, Table S1)
Among the women who died, 346 (72.0%) died from
bleeding (Fig. 1). Of those who died within 3 h of deliv-
ery, 91.0% were due to bleeding. Of those who died
within 24 h of delivery, 83.0% were due to bleeding. The
primary cause of haemorrhage in most women was uter-
ine atony, which cause the death of 53.2% of the women
who died (Table 1). The primary cause of haemorrhage
was recorded as “Other/Unknown” for 1704 women, 87
of whom died (OR = 2.62, 95%CI = 2.04–3.36).
The women who died lost on average 2.1 L (SD = 0.9
L, median = 2 L, IQR = 1.5–2.5 L), whereas those who
lived lost on average 1.2 L of blood (SD = 0.6 L, median =
1 L, IQR = 0.8–1.5 L). Among the women who died
92.1% received a blood transfusion, whereas 53.8% of
those who lived received one. Women who died received
a mean of 4.4 units (SD = 3.4) of transfused blood. Blood
was often unavailable, either because of blood shortages
or because relatives could not afford to purchase it.
“She delivered outside our hospital and was
admitted in our facility haemorrhaging. She stopped
bleeding after she was resuscitated but
unfortunately, was not able to get blood transfused.
Our hospital hardly gets voluntary blood donors. We
get blood mainly from 'coerced' donors, i.e. relatives
and caregivers of patients that require blood
transfusion, surgery etc. Emergencies (like this
patient) get blood if the blood bank is well stocked at
the time or if they have funds (most of our patients
do not, unfortunately) to source blood from private
banks which we can transfuse. This woman's blood
group was not available and she was unable to
procure blood from elsewhere. She died because we
could not replace all that she had lost (and I'm sure
she had lost a great deal before she got to us).”
(quote 130, Table S1)
“Admitted with cord prolapse. Had caesarean
section to a fresh stillbirth. While in the recovery
developed PPH which was controlled with oxytocin
and misoprostol. Developed PPH again at 09:00hrs
with uterine atony, same intervention initiated.
Noted to be still bleeding by 10:15hrs, decision to
take her back to theatre for hysterectomy made,
transferred to theatre, actively bleeding, tried to get
blood for blood transfusion but her blood type not
available in our unit and regional blood transfusion
Fig. 1 Causes of death for the 483 women who died in the WOMAN trail. The other causes included eclampsia, amniotic fluid embolism,
anaesthetic complication, aspiration pneumonia, blood transfusion reaction, diabetic ketoacidosis, HELLP syndrome, uremic encephalopathy, and
unknown causes
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centre. Mother died on the operating table at intub-
ation before hysterectomy at 11:40hrs.” (quote 212,
Table S1)
“Ruptured uterus was diagnosed during surgery;
doctors proceeded to Caesarean hysterectomy. She
suffered a first arrest during conversion from
regional to general anaesthesia. Was resuscitated
successfully. ... Haemostasis had been secured before
2nd cardiopulmonary arrest. CPR was performed till
she was certified dead at 10:57. Patient had since
stopped bleeding, but there was delayed replacement
of lost blood (she had no money, and it took a while
to get a credit deferment form). We think cause of
death was a combination of allergic reaction to
anaesthetic agents and blood loss.” (quote 172,
Table S1)
Although most deaths were from bleeding, 28.4% (137
women) were from non-bleeding causes of which organ
failure and sepsis were the most common (Fig. 1). The
“other” category includes deaths from eclampsia, amni-
otic fluid embolism, anaesthetic complication, aspiration
pneumonia, blood transfusion reactions, diabetic ketoa-
cidosis, HELLP syndrome (haemolysis, elevated liver en-
zyme levels, and low platelet levels) and uremic
encephalopathy.
“She had severe hypertension superimposed with pre-
eclampsia, complicated by renal failure and cortical
blindness. When she became poorly, the last
assessment that was made before she died was of a
blood transfusion reaction (from a transfusion which
was discontinued, then found to be type-
incompatible). That is the more probable cause of
death.” (quote 111, Table S1)
“The patient was referred with PPH. Severe pre-
eclampsia diagnosed in our hospital. Liver and
kidney functions deranged severely. HELLP syndrome
diagnosed. There was sign of stroke. Laparotomy
done due to an impression of hematoma collection
in the peritoneal space.” (quote 120, Table S1)
“She had Caesarean section on account of severe pre-
eclampsia and developed postpartum haemorrhage
from uterine atony afterwards. She … had
uterotonics administered and transfused with 2 units
of whole blood and active bleeding subsided … .
However, she developed pulmonary oedema and
subsequently died of respiratory failure. This was
mainly a complication of the severe preeclampsia.”
(quote 133, Table S1)
“Reading through the evidence, I would say the cause
of death is overwhelming sepsis [ … ] Yes, sepsis
definitely occurred. She had high-grade fever,
tenderness over the uterus and antibiotics were
procured irregularly (remember, it is pay-as-you-go
around here).” (quote 116, Table S1)
“The patient died at 19:30hrs … , the bleeding
stopped after administration of … but went into
cardiopulmonary arrest while awaiting blood
transfusion and died despite efforts to resuscitate
her. The baby was severely asphyxiated and died
shortly after birth.” (quote 164, Table S1)
Discussion
By preventing and treating PPH, we hope to avoid ma-
ternal deaths from PPH. To achieve this, the WHO has
developed a set of recommendations for the prevention
and treatment of PPH, focusing on medical and surgical
interventions, and their implementation. Based on the
WOMAN trial results [5], TXA was added to these rec-
ommendations [9].
With 20,060 patients and 483 maternal deaths, ours is
one of the largest studies of women with PPH ever con-
ducted. Because we conducted the WOMAN trial in
countries where the burden of maternal death from PPH
is highest, our findings are directly relevant to these
countries. A potential limitation to our study is that we
obtained narratives on 52% of the maternal deaths in the
WOMAN trial. We selected the narratives shown be-
cause they provided context for the quantitative data
about the women who died. The full set of narratives is
available for review in the supplement (Table S1). An-
other limitation is that nearly half of the narratives
(49%) came from one African country, which may be
due to the high number of women recruited to the trial
in that country. As a result, we cannot make clear infer-
ences on the state of the health care in that country
compared to others because the number of women re-
cruited to the trial varied greatly among countries. Simi-
larly, because only one high income country participated
to the trial and the trial was not meant to compare
health facilities in high income countries vs. low- and
middle-income ones, we cannot draw conclusions on the
effect of quality of care on mortality.
Although the risk of death was higher for women who
delivered outside of hospital, we cannot draw inferences
about the relative safety of home versus hospital delivery
on the basis of this study. Another problem is the lack
of records on the amount of blood that patients lost be-
fore the hospital admission, and that may have caused
life-threatening consequences. The women who were
transferred to hospital for urgent management would be
the most severely bleeding patients and would not be a
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representative sample of all women who develop PPH.
As a result of this selection bias we should not make any
causal inference. In some low and middle-income coun-
tries, about 40% of women deliver at home [10] with
only rudimentary transport in the event of an obstetric
emergency. Although health workers attend most births,
most cannot give intravenous drugs. Transport to hos-
pital can take hours, and many women exsanguinate be-
fore arrival. Our data show that many women arrived in
a critical condition and died soon after arrival. Early
intravenous TXA reduces death from bleeding, but this
is not an option for many thousands of women who de-
liver outside healthcare facilities. Intramuscular TXA has
the potential to increase timely access to this life saving
drug. Most health workers can give IM oxytocin and
could give IM TXA if shown to be effective. The World
Health Organization (WHO) has recommended that re-
search into other routes of administration of TXA is a
priority [9], and this research is in progress.
Many women do not deliver in hospitals because of
costs, education or the perception or accessibility of
health services [4, 11–16]. Studies on the factors that
affect maternal mortality extensively used the three de-
lays model examining barriers on the demand side
(phases 1 and 2 delay) and on the supply side (phase 3
delay) [17] to understand and intervene on the barriers
to prevent maternal death [4, 11–16].
According to the records, bleeding was the leading
cause of death. Most women in our study received treat-
ments aimed to prevent and stop blood loss, and, im-
portantly, they also received blood transfusions (92.1%),
which should help preventing death in case of major
PPH [18]. However, some of the narratives revealed that
sometimes the amount of blood transfused might not
have been sufficient, or the required blood type was not
available, or that the patient or her family could not af-
ford to buy more blood units. Hence, in developing
countries availability of blood for transfusion may be a
factor that leads to maternal deaths. This agrees with
other studies showing that poverty, lack of donors and
logistic problems contribute to scarcity of safe blood in
low- and middle-income countries [19–25]. However,
our study cannot confirm that deficit of blood transfu-
sion was a cause of death, nor that the transfusion was
administered too late. The actual impact of safe blood
availability on patients’ health, and how to address blood
shortage should be the subject of further research in de-
veloping countries [24]. Research and interventions
should target diverse areas such as increasing informa-
tion to donors on safety of donations, the possibility of
blood donations before delivery rather than after, finan-
cing steady blood availability within countries.
A little more than a quarter (28.4%) of the 483 women
died of causes other than bleeding. Most of the women
who died more than 24 h after giving birth (60.2%) died
of causes other than bleeding, whereas among the
women who died within 24 h from giving birth 85% of
them died because of bleeding. This suggests a temporal
shift in the causes of death, with bleeding being more
important early on. The narratives show that these
women had concurrent health complications that often
lead to organ or respiratory failures, or death due to sep-
sis. In one narrative, sepsis, which caused the death of
5% of the 483 women, lead to the death of the patient
because she could not buy the necessary antibiotics. In
another case, the patient died because of she received a
transfusion with the wrong blood type. To prevent trans-
fusion errors, which result in harmful consequences to
patients, waste of blood and money, new low-cost
methods should be researched and developed to improve
areas like patient identification, sample labelling or
obtaining the correct blood type [24, 26–28].
The number of stillbirths was higher for the women
who died than the women who lived. Based on our data,
it is not possible to conclude the causal direction be-
tween stillbirths and the mothers’ complications and
deaths. The issue around the causes of stillbirths is a
problem at a worldwide level because of the poor quality
of information, and the classification of causes is incon-
sistent between low-, middle-, and high-income coun-
tries [29, 30].
Several narratives highlighted the contribution of an-
aemia to maternal death. Although we did not measure
haemoglobin on all women, a sub-study conducted at
University College Hospital, Ibadan (Nigeria) [31–33],
showed that most (88%) women were anaemic (haemo-
globin < 110 g/L) and 40% were severely anaemic
(haemoglobin < 70 g/L) at the time of PPH onset [31].
Women with such low haemoglobin levels have little
physiological reserve and even mild to moderate bleed-
ing can have serious consequences. Anaemia is caused
by iron deficiency, micronutrients deficiency, infections,
and disorders of haemoglobin synthesis, and is highly
prevalent in Africa and South-East Asia [34]. Maternal
anaemia increases the risk of PPH and the likelihood of
severe morbidity or death should PPH occur [35, 36].
Blood shortages would exacerbate the risk from mater-
nal anaemia. Several of the narratives highlighted the ab-
sence of blood for transfusion due to availability or cost.
Poverty, lack of donors and logistic problems contribute
importantly to blood shortages [19–25]. For women with
severe anaemia, treatment of an established PPH is often
too late to prevent death and effective prevention is
needed. The WOMAN-2 trial will evaluate the effect of
TXA for the prevention of PPH in high-risk anaemic
women [37].
Although women who delivered outside of the hospital
had a substantially higher case fatality, the case fatality
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of women who delivered in hospital was 1.9%. The data
presented here highlight some of the factors that may
account for this high hospital case fatality rate including
the lack of timely intervention, inadequate infrastructure,
maternal anaemia with limited access to safe blood
transfusion and other important maternal co-morbidities
that increase the risk of death. Whilst it seems unlikely
that we will achieve maternal death rates comparable to
those in high-income settings without addressing these
structural issues, it is important to note that early ad-
ministration of TXA reduced the risk of death due to
bleeding by almost one third despite these constraints.
Indeed, further analyses of the WOMAN trial data sug-
gest that many women were so critically ill at the time
of randomisation that their death was imminent and in-
evitable regardless of treatment [38]. This raises the pos-
sibility that if women are treated very soon after
bleeding onset, as recommended by the WHO, the effect
of TXA on reducing the risk of death due to bleeding
may exceed that observed in the WOMAN trial.
Conclusions
This study highlights factors contributing to death after
PPH. Blood loss was the leading cause of death and the
narratives emphasise the lack of blood for transfusion ei-
ther from blood shortages or the inability to pay for it
when available. This is particularly important for women
with anaemia. Many women gave birth outside hospital
and were transferred for treatment in a critical condi-
tion. These narratives, collected in the context of a ran-
domised trial of tranexamic acid for women with PPH,
underscore the contribution of the healthcare infrastruc-
tures to the unacceptably high maternal mortality from
post-partum haemorrhage in many low and middle in-
come settings.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12884-020-03091-8.
Additional file 1: Table S1. Narratives dataset. Full set of narratives
analysed in this study.
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